Topical Safety Study of Topical Diltiazem Hydrochloride

• ClinicalTrials.gov Identifier: NCT01816529
• Recruitment Status: Unknown
• First Posted: March 22, 2013
• Last Update Posted: August 21, 2013
• Sponsor: Ventrus Biosciences, Inc
• Information provided by (Responsible Party): Ventrus Biosciences, Inc

Study Description

Brief Summary:

The goal of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions.

Condition or disease	Intervention/treatment	Phase
Diltiazem Skin Sensitivity.	Drug: Diltiazem Hydrochloride 2% Cream; Drug: Vehicle Cream; Drug: 0.1% solution of sodium lauryl sulfate (SLS); Drug: Saline (0.9%)	Phase 1

Detailed Description:

The primary objective of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream and its vehicle to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions. In addition, the irritation potential of the investigational products will be assessed during the Induction Phase and safety will be assessed by evaluation of any adverse events (AEs) reported during the study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 200 participants
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects Using a Repeat Insult Patch Test Design
• Study Start Date: March 2013
• Actual Primary Completion Date: June 2013
• Estimated Study Completion Date: September 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Topical Diltiazem Hydrochloride 2% Cream; 0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.	Drug: Diltiazem Hydrochloride 2% Cream; 0.2 g applied topically to the infrascapular area of the back.
Placebo Comparator: Vehicle Cream; 0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.	Drug: Vehicle Cream; Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
Active Comparator: 0.1% solution of sodium lauryl sulfate (SLS); 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.	Drug: 0.1% solution of sodium lauryl sulfate (SLS); 0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
Placebo Comparator: 0.9% Saline; 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.	Drug: Saline (0.9%); 0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.

Outcome Measures

Primary Outcome Measures :

1. Determine the potential of Diltiazem Hydrochloride 2% Cream to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions. [ Time Frame: 6 weeks after the first topical application ]
   A total cumulative irritation score for each subject and product will be calculated by summing each individual's scores on each of the 9 evaluation days in the Induction Phase. Cumulative irritancy during Induction will be quantified by means of the cumulative irritancy index (CII), defined as the mean of irritation scores received during the Induction Phase (9 readings). The determination of dermal sensitization potential will be based on specific scoring criteria derived from observations in the Challenge Phase of the study and confirmed in the Rechallenge Phase, if necessary. The recurrence of a cutaneous response at Rechallenge equivalent to or more severe than that observed at challenge will be considered indicative of a sensitization reaction. The observation of such a response in even a single subject suggests that the test product may have the potential to cause hypersensitivity.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Are healthy males or females (to be confirmed by medical history);
• Are 18 years of age or older;
• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
• In the case of females of childbearing potential: have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at the end of study (EOS);
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
• Read, understand, and provide signed informed consent.

Exclusion Criteria:

• Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs);
• Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history);
• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
• Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
• Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
• Have psoriasis and/or active atopic dermatitis/eczema;
• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
• Have a known sensitivity to constituents present in the material being evaluated;
• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
• Have received treatment for any type of internal cancer within 5 years prior to study entry;
• Have a history of, or are currently being treated for skin cancer;
• Are currently participating in any clinical testing,
• Have any known sensitivity to adhesives; and/or
• Have received any investigational treatment(s) within 4 weeks prior to study entry.

Contacts and Locations

Locations

United States, New Jersey

TKL Research

Paramus, New Jersey, United States, 07652

Sponsors and Collaborators

Ventrus Biosciences, Inc

More Information

• Responsible Party: Ventrus Biosciences, Inc
• ClinicalTrials.gov Identifier: NCT01816529
• Other Study ID Numbers: VEN307-DERM-001
• First Posted: March 22, 2013
• Last Update Posted: August 21, 2013
• Last Verified: July 2013

Additional relevant MeSH terms:

Hypersensitivity; Immune System Diseases; Diltiazem; Antihypertensive Agents; Calcium Channel Blockers; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Calcium-Regulating Hormones and Agents; Physiological Effects of Drugs; Vasodilator Agents